Thomas Soeiro

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Health risks associated with non-medical use of ketamine in France: National surveillance insights from the French Addictovigilance Network, 2019-2023.

Health risks associated with non-medical use of ketamine in France: National surveillance insights from the French Addictovigilance Network, 2019-2023.

Journal: Journal of psychopharmacology (Oxford, England)

Published: February 23, 2026

Factors Associated With Cocaine Use Disorder: Results From the French Nationwide Repeated Cross-Sectional OPPIDUM Study (2019-2023).

Factors Associated With Cocaine Use Disorder: Results From the French Nationwide Repeated Cross-Sectional OPPIDUM Study (2019-2023).

Journal: Fundamental & clinical pharmacology

Published: June 04, 2025

Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database.

Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: February 26, 2025

High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study.

High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study.

Journal: The Lancet regional health. Europe

Published: February 19, 2025

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment.

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment.

Journal: British journal of clinical pharmacology

Published: January 06, 2025

Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessment.

Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessment.

Journal: Therapie

Published: November 04, 2024

Can large language models detect drug-drug interactions leading to adverse drug reactions?

Can large language models detect drug-drug interactions leading to adverse drug reactions?

Journal: Therapeutic advances in drug safety

Published: October 24, 2024

Monitoring opioid analgesic misuse, abuse and dependence: What to the data from addictovigilance tell us about the situation in France?

Monitoring opioid analgesic misuse, abuse and dependence: What to the data from addictovigilance tell us about the situation in France?

Journal: Therapie

Published: September 30, 2024

Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.

Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.

Journal: Therapie

Published: September 26, 2024

Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.

Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.

Journal: CNS drugs

Published: August 30, 2024

Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?

Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?

Journal: Therapie

Published: June 17, 2024

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.

Journal: CNS drugs

Published: May 02, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026